TALLAHASSEE, Fla., Nov. 15, 2012 /PRNewswire/ -- Global Green, Inc. (OTCBB: GOGC) today announced that Dr. Mehran Ghazvini and Dr. Rene Reed will be making a joint presentation on "Creating the world's first in-ovo salmonella vaccine for chicken" at the 2012 World Animal Health Congress, a senior-level B2B conference for animal drug companies, on Wednesday, November 28.
Dr. Ghazvini, Chairman and CEO of Global Green, will also be included in a panel session entitled "Improving yields and decreasing disease to meet worldwide food demands." The panel immediately follows the Global Green joint presentation.
The Congress, a senior-level B2B conference for animal drug companies to be held November 27 and 28 in Kansas City, Missouri, showcases innovation in animal health, featuring senior-level speakers from the pharma, biotech, diagnostics and government sectors including Novartis, Merial, the USDA and the FDA. It provides an unrivaled platform to expose the most pressing business challenges of the industry. www.terrapinn.com/animalhealth
Terrapinn, a business media company and the sponsor for the Congress, will be distributing Global Green's White Paper entitled "Combating the Deadly Effects of Salmonella with Salmogenics" across multiple digital channels, including Twitter, LinkedIn, email blasts promoting the conference, and will be included in Terrapinn's Total BioPharma blog. The White Paper addresses the economic and environmental benefits of the Salmogenics vaccine.
Dr. Ghazvini commented, "The World Animal Health Congress is the industry's only global, commercially-focused animal health conference. It is an affirmation of our salmonella vaccine, Salmogenics, that we have been invited to speak at this conference."
Salmogenics helps to fight multiple strains of Salmonella bacteria in poultry. It is unique in that it is injected directly into the egg, before the chick is hatched, improving the immune system, health and welfare of the chicken, and providing a healthier source of protein for humans in a cost effective manner.
Global Green, Inc. is a green pharmaceutical company committed to identifying technology platforms and commercializing products that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards. Salmogenics, the Company's flagship product, was developed by Nutritional Health Institute Laboratories, LLC, a research affiliate and majority shareholder. The vaccine is currently in the final stage of the USDA approval process. For more information, visit www.globalgreeninc.org.
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties, which include among others, the inherent uncertainties associated with smaller reporting companies, including without limitation, other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
SOURCE Global Green, Inc.